Harris Ioannidis

Harris Ioannidis

Auto-generated profile, based on publicly available information

Harris Ioannidis

European Molecular Biology Laboratory, European Bioinformatics Institute, Hinxton, United Kingdom

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in Journal of Molecular Biology
Verified
Journal Article
Open access
CGCharis Georgiou
Charis Georgiou
IMIain McNae
Iain McNae
MWMartin Wear
Martin Wear
HIHarris Ioannidis
Harris Ioannidis
JMJulien Michel
Julien Michel
MWMalcolm Walkinshaw
Malcolm Walkinshaw
Fragment-based drug discovery is an increasingly popular method to identify novel small-molecule drug candidates. One of the limitations of the approach is the difficulty of accurately characterizing weak binding events. This work reports a combination of X-ray diffraction, surface plasmon resonance experiments and molecular dynamics simulations for the characterization of binders to different isoforms of the cyclophilin (Cyp) protein family. Although several Cyp inhibitors have been reported in the literature, it has proven challenging to achieve high binding selectivity for different isoforms of this protein family. The present studies have led to the identification of several structurally novel fragments that bind to diverse Cyp isoforms in distinct pockets with low millimolar dissociation constants. A detailed comparison of the merits and drawbacks of the experimental and computational techniques is presented, and emerging strategies for designing ligands with enhanced isoform specificity are described.

23 October 2018 in Chemical Science
Verified
Journal Article
Open access
PDF file
ASAlessio De Simone
Alessio De Simone
CGCharis Georgiou
Charis Georgiou
HIHarris Ioannidis
Harris Ioannidis
AGArun A. Gupta
Arun A. Gupta
JJJordi Juarez-Jimenez
Jordi Juarez-Jimenez
JMJulien Michel
Julien Michel
Molecular simulations led to the discovery of a new class of small molecules that inhibit the cyclophilin family of proteins.

15 January 2020 in Chemical Science
Verified
Journal Article
Open access
PDF file
JJJordi Juarez-Jimenez
Jordi Juarez-Jimenez
AGArun A. Gupta
Arun A. Gupta
GKGogulan Karunanithy
Gogulan Karunanithy
AMAntonia S. J. S. Mey
Antonia S. J. S. Mey
CGCharis Georgiou
Charis Georgiou
JMJulien Michel
Julien Michel
Proteins need to interconvert between many conformations in order to function, many of which are formed transiently, and sparsely populated. Particularly when the lifetimes of these states approach the millisecond timescale, identifying the relevant structures and the mechanism by which they interconvert remains a tremendous challenge. Here we introduce a novel combination of accelerated MD (aMD) simulations and Markov state modelling (MSM) to explore these ‘excited’ conformational states. Applying this to the highly dynamic protein CypA, a protein involved in immune response and associated with HIV infection, we identify five principally populated conformational states and the atomistic mechanism by which they interconvert. A rational design strategy predicted that the mutant D66A should stabilise the minor conformations and substantially alter the dynamics, whereas the similar mutant H70A should leave the landscape broadly unchanged. These predictions are confirmed using CPMG and R1ρ solution state NMR measurements. By efficiently exploring functionally relevant, but sparsely populated conformations with millisecond lifetimes in silico, our aMD/MSM method has tremendous promise for the design of dynamic protein free energy landscapes for both protein engineering and drug discovery.

9 May 2016 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
HIHarris Ioannidis
Harris Ioannidis
Antonios DrakopoulosAntonios Drakopoulos
Antonios Drakopoulos
CTChristina Tzitzoglaki
Christina Tzitzoglaki
NHNadine Homeyer
Nadine Homeyer
FKFelix Kolarov
Felix Kolarov
AKAntonios Kolocouris
Antonios Kolocouris

19 September 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
FHFiona M. I. Hunter
Fiona M. I. Hunter
HIHarris Ioannidis
Harris Ioannidis
ABA. Patrícia Bento
A. Patrícia Bento
NBNicolas Bosc
Nicolas Bosc
SCSybilla Corbett
Sybilla Corbett
ALAndrew R. Leach
Andrew R. Leach
ChEMBL is a large-scale, open-access, FAIR database of bioactive molecules with drug-like properties. ChEMBL 35 contains 17,500 approved drugs, and drugs that are progressing through the clinical development pipeline. Drug curation has formed an integral part of the core offering of the ChEMBL database since its inception. The paper is a reference guide to present the principles of why the ChEMBL drug data has been curated in a particular manner so that data users can better understand the nature of the data. The drug data include information on: names, synonyms and trade names, chemical structure or biological sequence, data sources, indications, mechanisms, warnings and drug properties such as maximum phase of development, type of molecule, prodrug status and first approval. The integrated nature of the drug data within the context of a bioactivity resource enables the wide use of the data set in drug discovery, AI and machine learning.

13 January 2016 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
NHNadine Homeyer
Nadine Homeyer
HIHarris Ioannidis
Harris Ioannidis
FKFelix Kolarov
Felix Kolarov
GGGünter Gauglitz
Günter Gauglitz
CZChristos Zikos
Christos Zikos
HGHolger Gohlke
Holger Gohlke